<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105165</url>
  </required_header>
  <id_info>
    <org_study_id>hanyi20210623</org_study_id>
    <nct_id>NCT05105165</nct_id>
  </id_info>
  <brief_title>Regulatory Mechanism of Orphanin FQ in Patients With Chronic Ischemic Heart Failure</brief_title>
  <official_title>Correlation Between Serum Orphanin FQ and β1-AR Autoantibodies in Patients With Chronic Ischemic Heart Failure and Its Regulatory Mechanism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Hospital of Shanxi Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      β 1 adrenergic autoantibody on cardiomyocytes β 1 adrenergic receptor increased the&#xD;
      occurrence of malignant arrhythmia in patients with chronic heart failure, accelerated&#xD;
      myocardial cell damage, and participated in sudden cardiac death. Our team found for the&#xD;
      first time that endogenous orphanin enkephalin promotes arrhythmia after acute myocardial&#xD;
      ischemia in rats, and its mechanism includes PKC pathway, regulation of action potential&#xD;
      duration and cell membrane surface β 1 adrenoceptor internalization disorder. At the same&#xD;
      time, N / OFQ can regulate the level of immune factors, and immune factors participate in the&#xD;
      formation of β1-aa. This study will be verified by clinical observation and animal&#xD;
      experiments: first, N / OFQ, IL-6 and chronic ischemic heart failure, and β 1-aa; second,&#xD;
      relationship between IL-6 gene 572G / C polymorphism and chronic ischemic heart failure&#xD;
      correlation of β 1-aa production; last, objective to verify whether N / OFQ is involved in&#xD;
      the regulation of IL-6 on chronic ischemic heart failure by knocking out N/ OFQ gene in the&#xD;
      animal model of chronic ischemic heart failure. So as to clarify the mechanism of myocardial&#xD;
      cell and extracellular injury, and find a new target for the treatment of chronic heart&#xD;
      failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum orphanin FQ was determined by enzyme linked immunosorbent assay</measure>
    <time_frame>24 hours</time_frame>
    <description>Serum N/OFQ levels</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Antibody positive group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibody negative group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Health Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Enzyme linked immunosorbent assay</intervention_name>
    <description>Determination of serum β 1-aa content</description>
    <arm_group_label>Antibody negative group</arm_group_label>
    <arm_group_label>Antibody positive group</arm_group_label>
    <arm_group_label>Health Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        During the study period, patients in the Department of Cardiology of the second hospital of&#xD;
        Shanxi Medical University were admitted.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic heart failure patients with reduced ejection fraction due to ischemic heart&#xD;
             disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Restrictive or hypertrophic cardiomyopathy, hypertensive cardiomyopathy, acute&#xD;
             myocarditis, acute coronary syndrome or acute myocardial infarction in the last 2&#xD;
             months, valvular disease (except mitral regurgitation secondary to left ventricular&#xD;
             dilation).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Hospital of Shanxi Medical University</investigator_affiliation>
    <investigator_full_name>Zheng Guo</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

